Lu Jianjun, Zhang Wei, Ding Yang, Li Xiang, Song Jiandong
Department of Gynaecology and Obstetrics, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, P.R. China.
Oncol Lett. 2019 May;17(5):4417-4422. doi: 10.3892/ol.2019.10117. Epub 2019 Mar 5.
The expression of microRNA (miR)-26b in ovarian carcinoma tissues, its correlation with clinicopathology, and its effect on diagnostic value and prognosis of ovarian cancer was investigated. A total of 74 patients with ovarian cancer (the study group) and 30 patients with benign ovarian tumors (the control group) in the Affiliated Hospital of Inner Mongolia Medical University from July 2011 to June 2013 were retrospectively analyzed. The expression of miR-26b in ovarian carcinoma tissues was detected by fluorescence reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and the correlation between the expression of miR-26b and the pathological features of ovarian carcinoma tissues and prognosis of patients was analyzed. The expression level of miR-26b in the study group (0.28±0.07) was significantly lower than that in the control group (0.54±0.11; P<0.050). There was no significant correlation between miR-26b expression and age, tumor type, exercise habit, smoking habit of patients with ovarian cancer (P>0.050), but there was close correlation between the miR-26b expression and lymph node metastasis, differentiation degree and pathological stage of patients with ovarian cancer (P<0.001). ROC curve showed that the area under curve (AUC) was 0.839, and when the maximum cut-off value was 0.815, the sensitivity and specificity of miR-26b in diagnosing the ovary was 84.932% and 77.936%, respectively. The 5-year overall survival rate in the low-expression group (61.54%) was significantly lower than that in the high-expression group (84.85; P=0.028). miR-26b is under-expressed in the ovary and has a close relationship with pathological stage, differentiation degree, and lymph node metastasis of ovarian cancer, which indicates that miR-26b is involved in the occurrence and development of ovarian cancer and is expected to be an effective indicator for treatment and diagnosis of ovarian cancer and the prognosis of patients.
研究了微小RNA（miR）-26b在卵巢癌组织中的表达情况、其与临床病理的相关性以及对卵巢癌诊断价值和预后的影响。回顾性分析了2011年7月至2013年6月内蒙古医科大学附属医院的74例卵巢癌患者（研究组）和30例卵巢良性肿瘤患者（对照组）。采用荧光逆转录定量聚合酶链反应（RT-qPCR）检测卵巢癌组织中miR-26b的表达，并分析miR-26b表达与卵巢癌组织病理特征及患者预后的相关性。研究组中miR-26b的表达水平为（0.28±0.07），显著低于对照组（0.54±0.11；P<0.050）。miR-26b表达与卵巢癌患者的年龄、肿瘤类型、运动习惯、吸烟习惯无显著相关性（P>0.050），但与卵巢癌患者的淋巴结转移、分化程度及病理分期密切相关（P<0.001）。ROC曲线显示曲线下面积（AUC）为0.839，当最大截断值为0.815时，miR-26b诊断卵巢癌的灵敏度和特异度分别为84.932%和77.936%。低表达组的5年总生存率（61.54%）显著低于高表达组（84.85；P=0.028）。miR-26b在卵巢中表达下调，与卵巢癌的病理分期、分化程度及淋巴结转移密切相关，这表明miR-26b参与了卵巢癌的发生发展，有望成为卵巢癌治疗、诊断及患者预后的有效指标。
